Antiviral Activity of Ergoferon against Group A Rotavirus
- Autores: Emelianova A.G.1, Shilovskii I.P.2, Sundukova M.S.2, Khaitov M.R.2, Epshtein O.I.1
- 
							Afiliações: 
							- Laboratory of Physiologically Active Substances, Department of Molecular and Cellular Pathology and Pathophysiology, Research Institute of General Pathology and Pathophysiology
- State Research Center Institute of Immunology, Federal Medical-Biological Agency
 
- Edição: Volume 161, Nº 6 (2016)
- Páginas: 806-807
- Seção: Virology
- URL: https://journals.rcsi.science/0007-4888/article/view/237801
- DOI: https://doi.org/10.1007/s10517-016-3516-x
- ID: 237801
Citar
Resumo
Antiviral activity of Ergoferon was studied in vitro on an experimental model of rotavirus infection in MA-104 cell line. In infected cells treated with Ergoferon, rotavirus titer was shown to decrease by 83 and 90% in comparison with cells treated with solvent used for Ergoferon preparation (p<0.05) and distilled water (p<0.05), respectively. These findings demonstrate high anti-rotavirus activity of Ergoferon.
Sobre autores
A. Emelianova
Laboratory of Physiologically Active Substances, Department of Molecular and Cellular Pathology and Pathophysiology, Research Institute of General Pathology and Pathophysiology
							Autor responsável pela correspondência
							Email: agemelianova@gmail.com
				                					                																			                												                	Rússia, 							Moscow						
I. Shilovskii
State Research Center Institute of Immunology, Federal Medical-Biological Agency
														Email: agemelianova@gmail.com
				                					                																			                												                	Rússia, 							Moscow						
M. Sundukova
State Research Center Institute of Immunology, Federal Medical-Biological Agency
														Email: agemelianova@gmail.com
				                					                																			                												                	Rússia, 							Moscow						
M. Khaitov
State Research Center Institute of Immunology, Federal Medical-Biological Agency
														Email: agemelianova@gmail.com
				                					                																			                												                	Rússia, 							Moscow						
O. Epshtein
Laboratory of Physiologically Active Substances, Department of Molecular and Cellular Pathology and Pathophysiology, Research Institute of General Pathology and Pathophysiology
														Email: agemelianova@gmail.com
				                					                																			                												                	Rússia, 							Moscow						
Arquivos suplementares
 
				
			 
						 
						 
						 
						 
					 
				 
  
  
  
  
  Enviar artigo por via de e-mail
			Enviar artigo por via de e-mail  Acesso aberto
		                                Acesso aberto Acesso está concedido
						Acesso está concedido Somente assinantes
		                                		                                        Somente assinantes
		                                					